title: Endogenous Kynurenine Aminotransferases Inhibitor is Proposed to Act as "Glia Depressing Factor" (GDF).
abstract: The endogenous neuroinhibitory amino acid receptor antagonist kynurenic acid (KYNA) has been hypothetically linked to physiological processes and to the pathogenesis of several brain disorders. The aim of this study was to search KYNA metabolism i.e. KYNA levels and enzymes synthesising KYNA kynurenine aminotransferase I and II (KAT I and II) in the central nervous system (CNS) and in the peripheral nervous system. Within the investigated species we found a remarkably low KYNA content (3.4 nM) in piglet's serum compared to rat and human serum. Furthermore, in contrast to high KAT activity present in rat and human livers, a lack of KAT I and KAT II activity was found in piglet liver and other piglet peripheral organs. Therefore we attempted to find a reason for the absence of KYNA formation in piglet peripheral tissue and we researched to find if KYNA formation in rat liver homogenate (measured under standard assay conditions for KAT activity) can be influenced by the application of piglet tissue homogenates and other body fluids. KYNA formation in rat liver homogenate was investigated in the presence of piglet liver, piglet brain, rat brain and human brain homogenates, and also in the presence of cerebrospinal fluid (CSF) of the control and of Multiple Sclerosis patients. We found a significant and dose dependent reduction of rat liver KAT I and KAT II activities in the presence of piglet brain, piglet liver, and human brain, but not in the presence of rat brain homogenate. Interestingly, CSF of the human control subjects significantly lowered rat liver KAT I activity. Furthermore, the inhibitory effect of CSF of Multiple Sclerosis (MS) patients was significantly weaker when compared to the CSF of control subjects. Our data, for the first time, indicated the presence of active component(s)-depressing factor-in the body, which was able to block KYNA formation. Reduced KAT inhibitory effect by CSF of MS patients would suggest a lowered "depressing factor" level in CSF of MS patients and is possibly responsible for an enhancement of KYNA formation and for glia activation and gliosis in the CNS. Subsequently, two fractions obtained after centrifugation of CSF from patients with Neuroborreliosis showed a significantly different ability to block KAT I activity. The CSF-sediment fraction exerts a stronger inhibitory activity than the CSF-supernatant fraction, supporting further the presence of a depressing factor. For the first time, data revealed and demonstrated the ability of endogenous components to block KYNA's synthesis. We propose that a glia depressing factor (GDF), which is abundantly present in the body, might simultaneously control glia cell's KAT activity, respectively KYNA synthesis and also glia proliferation. The mechanism(s) of action, the composition and structure of this factor needs to be further elaborated.
authors.affiliation: Neurochemical Laboratory, Karl Landsteiner Research Institute for Pain Treatment and Neurorehabilitation, LKM Mauer-Amstetten.
authors.forename: Halina
authors.initials: H
authors.lastname: Baran
authors.forename: Berthold
authors.initials: B
authors.lastname: Kepplinger
authors.forename: Markus
authors.initials: M
authors.lastname: Draxler
references.citation: Brain Res. 1991 Mar 1;542(2):307-12
references.pmid: 2029638
references.citation: J Neuroimmunol. 1992 Sep;40(1):71-80
references.pmid: 1387655
references.citation: Physiol Rev. 2009 Jan;89(1):73-120
references.pmid: 19126755
references.citation: Biol Psychiatry. 2001 Oct 1;50(7):521-30
references.pmid: 11600105
references.citation: J Neurochem. 1988 Jul;51(1):177-80
references.pmid: 3379401
references.citation: Magn Reson Med. 1989 Sep;11(3):337-48
references.pmid: 2779421
references.citation: J Neurosci. 2001 Oct 1;21(19):7463-73
references.pmid: 11567036
references.citation: Brain Res. 1992 Aug 14;588(1):1-5
references.pmid: 1393560
references.citation: Brain Res Dev Brain Res. 1996 Mar 29;92(1):111-6
references.pmid: 8861729
references.citation: J Neurochem. 1989 May;52(5):1629-36
references.pmid: 2709016
references.citation: Scand J Clin Lab Invest. 1977 Sep;37(5):385-90
references.pmid: 337459
references.citation: Eur J Pharmacol. 1995 Nov 14;286(2):167-75
references.pmid: 8605953
references.citation: Behav Neural Biol. 1993 Sep;60(2):89-92
references.pmid: 8117242
references.citation: Pediatr Res. 1997 Mar;41(3):404-10
references.pmid: 9078543
references.citation: Neuroscience. 1993 Jul;55(1):177-84
references.pmid: 8350986
references.citation: Psychopharmacology (Berl). 1995 Aug;120(4):463-9
references.pmid: 8539328
references.citation: Neurosignals. 2005;14(3):126-35
references.pmid: 16088227
references.citation: Life Sci. 2001 Aug 3;69(11):1249-56
references.pmid: 11521749
references.citation: J Neurosci Res. 1997 Nov 1;50(3):457-65
references.pmid: 9364331
references.citation: Anal Biochem. 1990 Mar;185(2):363-76
references.pmid: 2339792
references.citation: Neurosci Lett. 1984 Aug 10;48(3):273-8
references.pmid: 6237279
references.citation: Neuroreport. 1999 Jan 18;10(1):61-5
references.pmid: 10094134
references.citation: Eur Neuropsychopharmacol. 2009 Mar;19(3):161-8
references.pmid: 19008081
references.citation: J Neurochem. 2001 Aug;78(4):842-53
references.pmid: 11520905
references.citation: Free Radic Biol Med. 1997;23(3):524-8
references.pmid: 9214592
references.citation: Adv Exp Med Biol. 1991;294:201-5
references.pmid: 1685292
references.citation: Clin Chem. 1984 Jul;30(7):1246-9
references.pmid: 6375900
references.citation: Pharmacol Rev. 1993 Sep;45(3):309-79
references.pmid: 8248282
references.citation: J Neural Transm (Vienna). 1999;106(2):165-81
references.pmid: 10226937
references.citation: J Neurochem. 1994 Feb;62(2):730-8
references.pmid: 8294935
references.citation: J Neural Transm (Vienna). 2005 Feb;112(2):269-82
references.pmid: 15657642
references.citation: Mol Cell Biol. 2009 Feb;29(3):784-93
references.pmid: 19029248
references.citation: Brain Res Brain Res Rev. 1990 Jan-Apr;15(1):41-70
references.pmid: 2163714
references.citation: Eur J Pharmacol. 1988 Sep 1;154(1):85-7
references.pmid: 2846328
references.citation: Life Sci. 2003 Jan 24;72(10):1103-15
references.pmid: 12505541
references.citation: J Comp Neurol. 1992 Dec 1;326(1):82-90
references.pmid: 1479071
references.citation: Neurochem Res. 1980 Mar;5(3):223-39
references.pmid: 6154900
references.citation: Prog Neurobiol. 2001 Jun;64(2):185-218
references.pmid: 11240212
references.citation: J Neural Transm Suppl. 2000;59:281-92
references.pmid: 10961440
references.citation: J Neural Transm (Vienna). 2000;107(10):1127-38
references.pmid: 11129102
references.citation: J Neural Transm Suppl. 2000;59:273-80
references.pmid: 10961439
references.citation: J Chromatogr. 1988 Sep 9;430(2):376-80
references.pmid: 3235510
references.citation: Eur J Biochem. 2004 Dec;271(23-24):4804-14
references.pmid: 15606768